Loading…
MiNK Therapeutics, Inc. is projected to decline to $10.91 by 2027, a -1% move from its current price of $11.05. INKT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $10.64 | $11.05 | $11.48 | +0.02% |
| Jul 14 | $10.48 | $11.05 | $11.67 | +0.04% |
| Jul 15 | $10.35 | $11.06 | $11.81 | +0.07% |
| Jul 16 | $10.25 | $11.06 | $11.93 | +0.09% |
| Jul 17 | $10.16 | $11.06 | $12.05 | +0.11% |
| Jul 18 | $10.08 | $11.06 | $12.15 | +0.13% |
| Jul 19 | $10.01 | $11.07 | $12.24 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.01 | $11.07 | $12.24 | +0.15% |
| Week 2 | $9.61 | $11.08 | $12.78 | +0.30% |
| Week 3 | $9.32 | $11.10 | $13.22 | +0.46% |
| Week 4 | $9.09 | $11.12 | $13.60 | +0.61% |
| Week 5 | $8.89 | $11.13 | $13.95 | +0.76% |
| Week 6 | $8.71 | $11.15 | $14.27 | +0.92% |
| Week 7 | $8.56 | $11.17 | $14.58 | +1.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers.
The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.
MiNK Therapeutics, Inc. (INKT) operates in the Healthcare sector as a clinical-stage biopharmaceutical company focused on iNKT cell therapies for cancer and immune-mediated diseases. The stock trades at $11.31 per share and has a market capitalization of $56.35M, ranking 4513 by market cap.
A major floor 22.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.5% below — buyers have tended to step in here.
The nearest ceiling, 15.5% above — a clean break opens room to run.
A major ceiling 28.6% above — clearing it would confirm fresh momentum.
Key INKT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INKT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.05 | Buy | $11.14 | Sell |
| MA 10 | $11.36 | Sell | $11.32 | Sell |
| MA 20 | $11.73 | Sell | $11.51 | Sell |
| MA 50 | $11.53 | Sell | $11.54 | Sell |
| MA 100 | $11.26 | Sell | $11.55 | Sell |
| MA 200 | $11.96 | Sell | $11.62 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.11 | Neutral |
| Stoch RSI (14) | 40.02 | Neutral |
| CCI (20) | -105.40 | Sell |
| Williams %R (14) | -71.91 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | -10.38 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 28.09 | Neutral |
| TRIX (15) | -0.05 | Sell |
| Awesome (5,34) | -0.67 | Sell |
| Ultimate (7,14,28) | 39.72 | Neutral |
| Momentum (10) | -0.26 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 10.80 | Buy |
| ADX (14) | 9.15 | Neutral |
| ATR (14) | 0.40 | Info |
Technical sentiment is bearish in the near term. The RSI(14) is 40, and the price is trading near key moving averages, with the SMA50 at $11.68 and the SMA200 at $12.14. Immediate support sits at $10.04 and resistance at $12.76. The 30-day price range spans from $8.75 to $14.62, indicating broad price movement within roughly a $5 band over the past month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.56 | $11.05 | $15.28 | 0% | Neutral | |
| $8.37 | $10.91 | $15.23 | -1% | Neutral | |
| $8.86 | $12.03 | $17.63 | +9% | Neutral | |
| $9.61 | $13.50 | $20.54 | +22% | Bullish | |
| $11.44 | $16.57 | $26.02 | +50% | Bullish | |
| $12.95 | $19.29 | $31.14 | +75% | Bullish | |
| $11.70 | $17.89 | $29.58 | +62% | Bullish | |
| $12.08 | $18.94 | $32.02 | +71% | Bullish | |
| $12.60 | $20.23 | $34.89 | +83% | Bullish | |
| $10.79 | $17.73 | $31.16 | +60% | Bullish | |
| $15.79 | $28.87 | $54.79 | +161% | Bullish | |
| $26.50 | $58.88 | $124.82 | +433% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $8.56 | $11.05 | $13.60 | +0.00% |
| August 2026 | $9.35 | $11.15 | $13.74 | +0.93% |
| September 2026 | $9.36 | $11.27 | $14.10 | +1.06% |
| October 2026 | $9.88 | $12.01 | $15.22 | +6.55% |
| November 2026 | $9.99 | $12.23 | $15.66 | +1.81% |
| December 2026 | $9.59 | $11.82 | $15.28 | -3.34% |
Click any year to see its month-by-month INKT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, INKT is projected to trade between $8.56 and $15.28, averaging $11.05 — a potential gain of 0% from today's $11.05. A consolidation phase looks the most probable path here.
MiNK Therapeutics, Inc.'s 2027 outlook centres on $10.91, within a $8.37 to $15.23 range. That is -1% versus the projected 2026 average. That marks a -1% change versus current levels. Price action looks broadly range-bound.
By 2028, INKT could reach as high as $17.63, with a base case around $12.03 and support toward $8.86 — roughly +9% from $11.05. A consolidation phase looks the most probable path here.
Expect INKT to range from $9.61 to $20.54 through 2029. The $13.50 average target implies a +22% move from current prices. That is up +12% on the projected 2028 average. Momentum favours further upside here.
The INKT price prediction for 2030 points to an average of $16.57 (low $11.44, high $26.02) — a potential gain of +50% on today's $11.05. Buyers look set to stay in control over this stretch.
In 2031, INKT is projected to trade between $12.95 and $31.14, averaging $19.29 — a potential gain of +75% from today's $11.05. That is up +16% on the projected 2030 average. Momentum favours further upside here.
MiNK Therapeutics, Inc.'s 2032 outlook centres on $17.89, within a $11.70 to $29.58 range. That is -7% versus the projected 2031 average. That marks a +62% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, INKT could reach as high as $32.02, with a base case around $18.94 and support toward $12.08 — roughly +71% from $11.05. Momentum favours further upside here.
Expect INKT to range from $12.60 to $34.89 through 2034. The $20.23 average target implies a +83% move from current prices. That is up +7% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The INKT price prediction for 2035 points to an average of $17.73 (low $10.79, high $31.16) — a potential gain of +60% on today's $11.05. Momentum favours further upside here.
In 2040, INKT is projected to trade between $15.79 and $54.79, averaging $28.87 — a potential gain of +161% from today's $11.05. That is up +63% on the projected 2035 average. Buyers look set to stay in control over this stretch.
MiNK Therapeutics, Inc.'s 2050 outlook centres on $58.88, within a $26.50 to $124.82 range. That is up +104% on the projected 2040 average. That marks a +433% change versus current levels. Momentum favours further upside here.
Investing $1,000 in INKT today (≈ 90.497738 INKT) could be worth
$5,328.55
+$4,328.55 (+433%) by 2050 · US Dollar
Based on the average projected INKT price of $58.88 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INKTwould be worth at today's price.
$1,000 invested in INKT on Jul 10, 2025 (≈ 129.366106 INKT) would be worth
$1,429.5
+$429.5 (+42.9%) today · 1.43× · US Dollar
Based on a INKT entry price of $7.73 vs. today's $11.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.67 | $946.87 | -5.3% |
| 1 month ago | $12.19 | $906.48 | -9.4% |
| 3 months ago | $11.04 | $1,000.91 | +0.1% |
| 6 months ago | $12 | $920.83 | -7.9% |
| 1 year ago | $7.73 | $1,429.5 | +42.9% |
| All time (4.7y) ago | $120 | $92.08 | -90.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INKT forecast.
Our base-case forecast reaches $22.00 around 2040.
Implied market cap at $22.00: $109.6M
The year-by-year forecast shows continued upside over the coming years. In 2026, the forecast average price is $11.31 with an ROI of 0% and neutral sentiment. By 2029 the average price is projected to $14.15 with a 25.1% ROI and bullish sentiment, and by 2030 the average price rises to $17.41 with a 53.9% ROI and bullish sentiment.
The outlook strengthens further through 2031–2034, with 2031 at $19.45 (72% ROI) and 2034 at $20.32 (79.6% ROI). The long-range view shows substantial upside in 2040 and 2050, with averages of $29.41 (160% ROI) in 2040 and $61.62 (444.8% ROI) in 2050, both bullish. These figures illustrate potential higher-sell scenarios, but they are estimates, not guarantees, and are subject to market and company developments.
Tap a question to reveal the answer.
The forecasted average price for 2030 is $17.41 with a 53.9% ROI and bullish sentiment.
The forecast shows a bullish path from 2029 onward, with average price rising to $17.41 by 2030 and $61.62 by 2050, and a maximum projected price of $131.99 in 2050, implying meaningful long‑term upside though short‑term results vary.
The maximum forecast for 2050 is $131.99, so reaching $100 is within the provided max scenario.
Current price is $11.31 and market cap is $56.35M.
The 2040 average forecast price is $29.41 with a 160% ROI and bullish sentiment.
MiNK Therapeutics, Inc. Community Discussion
0Share your MiNK Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.